Limb girdle muscular dystrophies: Classification, clinical spectrum and emerging therapies

Current Opinion in Neurology

Volumn 29, Issue 5, 2016, Pages 635-641

  Vissing, John ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Classification; Limb girdle muscular dystrophy; Therapy

Indexed keywords

CLINICAL FEATURE; DISEASE CLASSIFICATION; DISTAL MYOPATHY; HEART DISEASE; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; METABOLIC DISORDER; MUSCLE METABOLISM; MYOGLOBINURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PHENOTYPE; REVIEW; CLASSIFICATION; GENOTYPE; SYMPTOM ASSESSMENT;

GENOTYPE; HUMANS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; SYMPTOM ASSESSMENT;

EID: 84982859364     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000375     Document Type: Review

References (44)

1. Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954; 77:169-231.
2. Schwartz M, Hertz JM, Sveen ML, Vissing J. LGMD2I presenting with a characteristic Duchenne or Becker dystrophy phenotype. Neurology 2005; 64:1635-1637.
3. Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81:27-40.
4. Zatz M, Starling A. Calpains and disease. N Engl J Med 2005; 352:2413-2423.
5. Norwood FL, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009; 132:3175-3186.
6. Guglieri M, Magri F, D'Angelo MG, et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008; 29:258-266.
7. Sveen ML, Schwartz M, Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol 2006; 59:808-815.
8. Duno M, Sveen ML, Schwartz M, Vissing J. cDNA analyses of CAPN3 enhance mutation detection and reveal a low prevalence of LGMD2A patients in Denmark. Eur J Hum Genet 2008; 16:935-940.
9. Kefi M, Amouri R, Driss A, et al. Phenotype and sarcoglycan expression in Tunisian LGMD2C patients sharing the same del521-T mutation. Neuromuscul Disord 2003; 13:779-787.
10. Spangos K, Walter MC, Dekomien G, et al. C283Y mutation in the gammasarcoglycan gene in Greek Gypsies with severe limb girdle muscular dystrophy. Eur J Neurol 2010; 17:e41-e42.
11. Gundesli H, Talim B, Korkusuz P, et al. Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes autosomal-recessive limb-girdle muscular dystrophy. Am J Hum Genet 2010; 87:834-841.
12. Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med 2011; 364:939-946.
13. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000; 9:2141-2147.
14. Saredi S, Gibertini S, Ardissone A, et al. A fourth case of POMT2-related limb girdle muscle dystrophy with mild reduction of (-dystroglycan glycosylation. Eur J Paediatr Neurol 2014; 18:404-408.
15. Gavassini BF, Carboni N, Nielsen JE, et al. Clinical and molecular characterization of limb girdle muscular dystrophy due to LAMA2 mutations. Muscle Nerve 2011; 44:703-709.
16. Løkken N, Born AP, Duno M, Vissing J. LAMA2-related myopathy; frequency among congenital and limb-girdle muscular dystrophies. Muscle Nerve 2015; 52:547-553.
17. Lindberg C, Sixt C, Oldfors A. Episodes of exercise-induced dark urine and myalgia in LGMD 2I. Acta Neurol Scand 2012; 125:285-287.
18. Dahlqvist JR, Vissing CR, Thomsen C, Vissing J. Severe paraspinal muscle involvement in facioscapulohumeral muscular dystrophy. Neurology 2014; 83:1178-1183.
19. Witting N, Duno M, Petri H, et al. Anoctamin 5 muscular dystrophy in Denmark; genotype, phenotype, prevalence, cardiology and muscle protein expression. J Neurol 2013; 260:2084-2093.
20. Sarkozy A, Deschauer M, Carlier RY, et al. Muscle MRI findings in limb girdle muscular dystrophy type 2L. Neuromuscul Disord 2012; 22 (Suppl 2):S122-S129.
21. Vissing J, Barresi R, Witting N, et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain 2016; 139:2154-2163.
22. Mercuri E, Bushby K, Ricci E, et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 2005; 15:164-171.
23. Paradas C, Llauger J, Diaz-Manera J, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 2010; 75:316-323.
24. Olivé M, Goldfarb LG, Shatunov A, et al. Myotilinopathy: refining the clinical and myopathological phenotype. Brain 2005; 128 (Pt 10):2315-2326.
25. Witting N, Andersen LK, Vissing J. Axial myopathy: an overlooked feature of myopathies. Brain 2016; 139 (Pt 1):13-22.
26. Willis TA, Hollingsworth KG, Coombs A, et al. Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 2013; 8:e70993.
27. ten Dam L, van der Kooi AJ, van Wattingen M, et al. Reliability and accuracy of skeletal muscle imaging in limb-girdle muscular dystrophies. Neurology 2012; 79:1716-1723.
28. Semplicini C, Vissing J, Dahlqvist JR, et al. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology 2015; 84:1772-1781.
29. Willis TA, Hollingsworth KG, Coombs A, et al. Resonance imaging in limbgirdle muscular dystrophy 2I: a multinational cross-sectional study. PLoS One 2014; 9:e90377.
30. Quick S, Schaefer J, Waessnig N, et al. Evaluation of heart involvement in calpainopathy (LGMD2A) using cardiovascular magnetic resonance. Muscle Nerve 2015; 52:661-663.
31. Sveen ML, Thune JJ, Køber L, Vissing J. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. Arch Neurol 2008; 65:1196-1201.
32. Petri H, Sveen ML, Thune JJ, et al. Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: a 9-year follow-up study. Int J Cardiol 2015; 182:403-411.
33. Anselme F, Moubarak G, Savouré A, et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm 2013; 10:1492-1498.
34. Vissing CR, Preisler N, Husu E, et al. Aerobic training in patients with myopathy and hyperCKemia caused by anoctamin 5 deficiency. Muscle Nerve 2014; 50:119-123.
35. Sveen ML, Jeppesen TD, Hauerslev S, et al. Endurance training: An effective and safe treatment for patients with LGMD2I. Neurology 2007; 68:59-61.
36. Berthelsen MP, Husu E, Christensen SB, et al. Antigravity training improves walking capacity and postural balance in patients with muscular dystrophy. Neuromuscul Disord 2014; 24:492-498.
37. Sveen ML, Andersen SP, Ingelsrud LH, et al. Resistance training in patients with limb girdle and Becker muscular dystrophies. Muscle Nerve 2013; 47:163-169.
38. Andersen SP, Sveen ML, Hansen RS, et al. Creatine kinase response to highintensity aerobic exercise in adult-onset muscular dystrophy. Muscle Nerve 2013; 48:897-901.
39. Rodino-Klapac LR,Haidet AM,Kota J, et al Inhibition ofmyostatinwithemphasis on follistatin as a therapy formuscle disease.MuscleNerve2009 39:283-296.
40. Walter MC, Reilich P, Thiele S, et al. Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 2013; 8:26.
41. Darin N, Kroksmark AK, Ahlander AC, et al. Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur J Paediatr Neurol 2007; 11:353-357.
42. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 2010; 68:629-638.
43. Grose WE, Clark KR, Griffin D, et al. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One 2012; 7:e39233.
44. Thompson R, Straub V. Limb-girdle muscular dystrophies: international collaborations for translational research. Nat Rev Neurol 2016; 12:294-309.